18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer

Christos Sachpekidis, A. Afshar-Oromieh, K. Kopka, D. S. Strauss, L. Pan, U. Haberkorn, A. Dimitrakopoulou-Strauss

Research output: Contribution to journalArticle

Abstract

Objectives: Aim of the present analysis is to investigate the biodistribution and pharmacokinetics of the recently clinically introduced radioligand 18F-PSMA-1007 in patients with biochemical recurrence or progression of prostate cancer (PC) by means of multiparametric (dynamic and whole-body) PET/CT. Methods: Twenty-five (25) patients with PC biochemical relapse or progression (median age = 66.0 years) were enrolled in the analysis. The median PSA value was 1.2 ng/mL (range = 0.1–237.3 ng/mL) and the median Gleason score was 7 (range = 6–10). All patients underwent dynamic PET/CT (dPET/CT) scanning (60 min) of the pelvis and lower abdomen as well as whole-body PET/CT with 18F-PSMA-1007. PET/CT assessment was based on qualitative evaluation, SUV calculation, and quantitative analysis based on a two-tissue compartment model and fractal analysis. Results: 15/25 patients were PET-positive. Plasma PSA values in the 18F-PSMA-1007 positive group were higher (median = 3.6 ng/mL; range = 0.2–237.3 ng/mL) than in the 18F-PSMA-1007 negative group (median value = 0.7 ng/mL; range = 0.1–3.0 ng/mL). Semi-quantitative analysis in the PC lesions demonstrated a mean SUVaverage = 25.1 (median = 15.4; range = 3.5–119.2) and a mean SUVmax = 41.5 (median = 25.7; range = 3.8–213.2). Time–activity curves derived from dPET/CT revealed an increasing tracer accumulation during the 60 min of dynamic PET acquisition into the PC lesions, higher than in the urinary bladder and the colon. Significant correlations were observed between 18F-PSMA-1007 uptake (SUV), influx, and fractal dimension (FD). Conclusions: 18F-PSMA-1007 PET/CT could detect PC lesions in 60% of the patients of a mixed population, including also patients with very low PSA values. Higher PSA values were associated with a higher detection rate. Dynamic PET analysis revealed an increasing tracer uptake during the dynamic PET acquisition as well as high binding and internalization of the radiofluorinated PSMA ligand in the PC lesions.

Original languageEnglish (US)
Pages (from-to)592-602
Number of pages11
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume47
Issue number3
DOIs
Publication statusPublished - Mar 1 2020

    Fingerprint

Keywords

  • Dynamic PET/CT
  • F-PSMA-1007
  • Multiparametric
  • Prostate cancer
  • Two-tissue compartment model

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Sachpekidis, C., Afshar-Oromieh, A., Kopka, K., Strauss, D. S., Pan, L., Haberkorn, U., & Dimitrakopoulou-Strauss, A. (2020). 18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 47(3), 592-602. https://doi.org/10.1007/s00259-019-04569-0